UW ramps up study of COVID-19 drug cocktail

Hydroxychloroquine and azithromycin

Hydrochloroquine and azithromycin will be the focus of a clinical trial enrolling 2,000 participants. (UW Medicine Photo)

One of the treatments that’s been talked up by President Donald Trump for COVID-19 — a combination of the antimalarial drug hydroxychloroquine and azithromycin, an antibiotic — is the subject of a nationwide study with UW Medicine playing a role.

The Phase 2b clinical trial, sponsored by the National Institute of Allergy and Infectious Disease at the National Institutes of Health, will involve 2,000 outpatients who have tested positive for COVID-19 and are in the early stages of treatment.

“We know from a number of different other kinds of infections that if antiviral treatment is going to be effective, it tends to be most effective if it’s given very early on,” Ann Collier, a professor at the University of Washington’s School of Medicine, said in a video about the study.

Get the full story on GeekWire.

About Alan Boyle

Aerospace and science editor for GeekWire, creator of Cosmic Log, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.
This entry was posted in GeekWire and tagged , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.